We are live on ! Find out more
CMMB

Chemomab Therapeutics
CMMB

13 hedge funds and large institutions have $2.07M invested in Chemomab Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more capital invested

Capital invested by funds: $1.47M → $2.07M (+$600K)

0.09% less ownership

Funds ownership: 0.33% → 0.23% (-0.09%)

24% less funds holding

Funds holding: 17 → 13 (-4)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Holders
13
Holders Change
-4
Holders Change %
-23.53%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$16.9K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$7.39K
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$1.54K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$89.5K
2
Citadel Advisors
Citadel Advisors
Florida
-$16.7K
3
XT
XTX Topco
Cayman Islands
-$14.8K
4
VF
Virtu Financial
New York
-$13K
5
Two Sigma Investments
Two Sigma Investments
New York
-$10.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$1.75M – – –
IC
2
Ikarian Capital
Texas
$166K – – –
Two Sigma Investments
3
Two Sigma Investments
New York
$31.2K -$10.5K -4,077 -29%
Two Sigma Advisers
4
Two Sigma Advisers
New York
$29.4K +$1.54K +600 +7%
KPWS
5
Kestra Private Wealth Services
Texas
$24.3K – – –
BFM
6
Boothbay Fund Management
New York
$20.7K – – –
TSS
7
Two Sigma Securities
New York
$20.4K +$16.9K +6,546 New
RhumbLine Advisers
8
RhumbLine Advisers
Massachusetts
$14.5K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$9.14K – – –
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$8.94K +$7.39K +2,869 New
Morgan Stanley
11
Morgan Stanley
New York
$2.18K -$89.5K -34,759 -98%
MWA
12
Moser Wealth Advisors
Washington
$390 – – –
Qube Research & Technologies (QRT)
13
Qube Research & Technologies (QRT)
United Kingdom
$34 – – –
JP Morgan Chase
14
JP Morgan Chase
New York
$1 – – –
Citadel Advisors
15
Citadel Advisors
Florida
– -$16.7K -8,169 Closed
XT
16
XTX Topco
Cayman Islands
– -$14.8K -7,262 Closed
VF
17
Virtu Financial
New York
– -$13K -6,452 Closed
Millennium Management
18
Millennium Management
New York
– -$10K -4,925 Closed
ASN
19
Advisory Services Network
Georgia
– -$2.44K -1,197 Closed
Osaic Holdings
20
Osaic Holdings
Arizona
– -$297 -146 Closed

CMMB Hedge Fund Activity: Q1 2024 in Review

13 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q1 2024, worth a combined $2.07M — up 41% from $1.47M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CMMB and 2 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $16.9K. The largest seller was Morgan Stanley, cutting an estimated $89.5K.

  • 13 institutional investors held Chemomab Therapeutics (CMMB) as of Q1 2024, down from 17 in Q4 2023.
  • Funds reported $2.07M of Chemomab Therapeutics stock for Q1 2024, up 41% quarter-over-quarter.
  • 2 funds opened new Chemomab Therapeutics positions in Q1 2024 and 6 closed out, a net change of -4 holders.
  • The largest Chemomab Therapeutics buyer in Q1 2024 was Two Sigma Securities, an estimated $16.9K added.
  • The largest Chemomab Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $89.5K sold.

Based on aggregated 13F filings for Q1 2024.